Sun Pharma FY24 Q4 Results: Net Profit Up By 34%

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharma company in India. The company has reported its Q4 FY 2023-24 earnings today.

Q4 Performance of Sun Pharma

Sun Pharma has recorded a surge in both bottom-line and top-line basis by 34% and 9.6% respectively for this quarter. The US sales have remained flat on a quarter-on-quarter basis at $476 Million Vs $477 Million.

Updates Regarding Research and Development 

The Company has said that its bR&D efforts span across both specialty and generic businesses and they will continue to invest in strengthening the product pipeline for various markets. The specialty R&D pipeline of the company comprises 6 molecules undergoing clinical studies. They also have a comprehensive product offering in the US market consisting of 531 approved ANDAs while filings for 104 ANDAs await US FDA approval, including 29 tentative approvals. Additionally, their portfolio includes 51 approved NDAs while 14 NDAs await US FDA approval. For the quarter, 11 ANDA were filed and 2 approvals were received.

Market Reaction After Results

The markets reacted positively to the results, As after the company reported its Q4 FY 2023-24 earnings, the stock went high to Rs.1561 from Rs.1519. The stock has given attractive returns of more than 65% over the past year and is up by 24% this year.

Conclusion: The company has reported a quarter-on-quarter surge in both revenue and net profits in this quarter’s earnings, While EBITDA margins have remained muted for this quarter. The board has also recommended a dividend of Rs.5 per equity share. The script closed at  Rs.1,539.30 a piece today.

Disclaimer: This post has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.